Inozyme Pharma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Inozyme Pharma sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).
Inozyme Pharma: 9 sponsored US clinical trials, 3 recruiting.
Inozyme Pharma sponsors 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 5 completed. 1 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, with 5 trials.
Top-decile sponsor footprint
Inozyme Pharma ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
9 total, page 1 of 1
PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 Deficiency
NCT06302439
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
NCT06462547
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
NCT05734196
The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency
NCT06046820
The SEAPORT 1 Study: Evaluation of the Safety and Tolerability of INZ-701 in Adults With End-Stage Kidney Disease Undergoing Hemodialysis
NCT06283589
Natural History Study of ENPP1 Deficiency and the Early-onset Form of ABCC6 Deficiency
NCT05050669
Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE
NCT05030831
Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency
NCT04686175
Understanding the Spectrum of ENPP1 Deficiency and Acute ABCC6 Deficiency
NCT04372446
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Inozyme Pharma pipeline
3 recruiting of 9 indexed (33% open); 5 completed (56%).
Phase mix: 1 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency (5 trials), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Inozyme Pharma: open-pipeline peers nationwide
Peers matched on 9 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Inozyme Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 9 trials (± recruiting share)
- 4D Molecular Therapeutics · 9 trials · 44% recruiting
- 9 Meters Biopharma · 9 trials · 0% recruiting
- Aadi Bioscience · 9 trials · 33% recruiting
- Ablynx, a Sanofi company · 9 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
- Adagio Medical · 33% recruiting · 3 trials
Related
What to do with this Inozyme Pharma page
9 registered trials is a research-attention snapshot, not an endorsement of Inozyme Pharma or any single study.
- 3 of Inozyme Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency is the condition Inozyme Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Inozyme Pharma pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.